Cipla is currently trading at Rs. 699.70, up by 62.60 points or 9.83% from its previous closing of Rs. 637.10 on the BSE.
The scrip opened at Rs. 696.00 and has touched a high and low of Rs. 696.00 and Rs. 665.00 respectively.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 696.00 on 22-Jun-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 696.00 and Rs. 632.00 respectively. The current market cap of the company is Rs. 51367.53 crore.
The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 40.61% and 22.71% respectively.
Cipla has launched remdesivir under its brand name CIPREMI. The USFDA issued an Emergency Use Authorization (EUA) to Gilead Sciences Inc. for emergency use of remdesivir for the treatment of hospitalized 2019 coronavirus disease (COVID-19) patients. It is the only USFDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalized with suspected or laboratory confirmed COVID-19 infection. In May, Gilead Sciences Inc. extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla’s generic version of remedisvir called CIPREMI.
The company has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need. As part of a risk management plan, the company will provide training on use of the drug, informed patient consent documents, conduct post marketing surveillance as well as conduct a Phase IV clinical trial on Indian patients.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
